Tirofiban: uses, dosing, side effects & brands

Tirofiban is a platelet aggregation inhibitor sold in the U.S. under one brand, for unstable angina, coronary disease and myocardial infarction. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Drug class: Platelet Aggregation Inhibitor
Treats: Unstable Angina, Coronary Disease and Myocardial Infarction
Available as: Injectable
Sold as: Aggrastat
Prescription?: Prescription only
Generic available?: Not in our catalog

How tirofiban is dosed

From the FDA label for Aggrastat (application NDA020912). Other tirofiban products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance ≤60 mL/min, give 25 mcg/kg within 5 minutes and then 0.075 mcg/kg/min. ( 2 ) 2.1 Recommended Dosage The recommended dosage is 25 mcg/kg administered intravenously within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. 2.2 Administration For intravenous use only. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. To open the 100 mL or 250 mL premixed bag, first tear off its foil overpouch. The plastic may be somewhat opaque because of moisture absorption during sterilization; the opacity will diminish gradually. Check for leaks by squeezing the inner bag firmly; if any leaks are found or sterility is suspect then the solution should be discarded. Do not use unless the solution is clear and the seal is intact. Administration Instructions Withdraw the bolus dose of AGGRASTAT from the 15 mL premixed bolus vial into a syringe. Alternatively, the bolus dose of AGGRASTAT may be administered from the 100 mL or 250 mL premixed bag. Do not dilute. Administer the bolus dose within 5 minutes via a syringe or IV pump. For patients ≥ 167 kg, it is recommended that the bolus dose be administered via syringe from the 15 mL premixed bolus vial, to…

Tirofiban side effects

Bleeding is the most commonly reported adverse reaction. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Medicure at 1-800-509-0544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the PRISM (Platelet Receptor Inhibition for Ischemic Syndrome Management), PRISM-PLUS (Platelet Receptor Inhibition for Ischemic Syndrome Management — Patients Limited by Unstable Signs and Symptoms) and RESTORE (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis) trials, 1946 patients received AGGRASTAT in combination with heparin and 2002 patients received AGGRASTAT alone for about 3 days. Forty-three percent of the population was >65 years of age and approximately 30% of patients were female. In clinical studies with the recommended regimen (25 mcg/kg bolus followed by a 0.15 mcg/kg/min maintenance infusion), AGGRASTAT was administered in combination with aspirin, clopidogrel and heparin or bivalirudin to over 8000 patients for typically ≤24 hours. Approximately 30% of the population was >65 years of age and approximately 25% were female. Bleeding PRISM-PLUS Regimen The…

Who shouldn’t take tirofiban

AGGRASTAT is contraindicated in patients with: Severe hypersensitivity reaction to AGGRASTAT (i.e., anaphylactic reactions) [see Adverse Reactions ( 6.2 )] . A history of thrombocytopenia following prior exposure to AGGRASTAT [see Adverse Reactions ( 6.1 )] . Active internal bleeding or a history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month [see Adverse Reactions ( 6.1 ) ]. Known hypersensitivity to any component of AGGRASTAT. ( 4 ) History of thrombocytopenia with prior exposure to AGGRASTAT. ( 4 ) Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month. ( 4 )

Tirofiban drug interactions

Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. Coadministration of fibrinolytics, anticoagulants and antiplatelet agents, increases the risk of bleeding. ( 7 )

Every tirofiban product we track (1)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Only one: Aggrastat.

Tirofiban recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

How long tirofiban keeps

No tirofiban label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.

Does tirofiban expire? The in-use limits and storage rules from its labels

What people report to the FDA about tirofiban

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 210 reports naming tirofiban, and the FDA flagged 94% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

thrombocytopenia31 reports
cerebral haemorrhage18 reports
platelet count decreased12 reports
acute myocardial infarction9 reports
haematemesis8 reports
myocardial infarction8 reports
nausea8 reports
shock haemorrhagic8 reports

Read these as a signal, not a rate. A report does not mean tirofiban caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved July 26, 2026.

Related calculators

How long it stays in your system →

Frequently asked questions

What is tirofiban?

Aggrastat (Tirofiban Hydrochloride) is a platelet aggregation inhibitor used to treat Unstable Angina, Coronary Disease, Myocardial Infarction.

What kind of drug is tirofiban?

The FDA classifies tirofiban as a platelet aggregation inhibitor. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

Can you take tirofiban with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run tirofiban against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What forms does tirofiban come in?

Across the brands we track, tirofiban is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic tirofiban?

We do not currently list a generic-labelled tirofiban product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Has tirofiban been recalled?

The FDA's Enforcement database lists 2 recall records whose product description mentions tirofiban. The most recent: Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL) (Apr 21, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Cite this page

APA: pharmaranks. (2026, July 24). Tirofiban: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/tirofiban
MLA: “Tirofiban: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/tirofiban.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for tirofiban on DailyMed (NIH) ↗.